Publications by authors named "Patricia de Paulo Giacon Radtke"
Long-Term Safety and Effectiveness of Rituximab Biosimilar RTXM83: A Retrospective Extension Study in Brazilian Patients with Diffuse Large B-Cell Lymphoma.
Marcia Torresan Delamain Ana Carolina Ferreira Cardoso Fernando Vieira Pericole Sérgio Shusterschitz da Silva Araújo Laura Fogliatto Patrícia de Paulo Giacon Radtke
Oncol Ther
September 2024
Article Synopsis
- RTXM83, a biosimilar to rituximab, has been approved after extensive studies showed it is similar to the original drug; this includes results from a pivotal study called RTXM83-AC-01-11.
- A retrospective study in Brazil analyzed long-term outcomes for patients with diffuse large B cell lymphoma (DLBCL) who received either RTXM83 or the original rituximab alongside other chemotherapy drugs, revealing that both groups showed significant progress in treatment.
- The findings highlighted that RTXM83 had a much higher progression-free survival and overall survival rate compared to the original drug, indicating its effectiveness and safety, although further research is needed to confirm these results in